Form 4: Bernd Seizinger Discloses Aptose Biosciences Share Changes

Bernd R. Seizinger, former director of Aptose Biosciences Inc., reported transactions involving common shares and stock options on June 30, 2026, related to a business arrangement agreement.

Summary

• Bernd R. Seizinger, previously a director at Aptose Biosciences Inc., has filed a Form 4 detailing transactions on June 30, 2026.
• These transactions include the disposal of 17,000 common shares and the exercise of stock options.
• The disposal of common shares was part of a board, shareholder, and court-approved business arrangement agreement with Hammi Pharmaceuticals Co. Ltd.
• Under this agreement, a subsidiary of Hammi acquired all outstanding shares of Aptose Biosciences at C$2.41 per share.
• The disposed shares were converted from Canadian dollars to USD at an exchange rate of C$1.4 = US$1.00, resulting in a price of approximately $1.72 per share.
• Seizinger also exercised stock options with exercise prices of $2.00, $0.66, and $0.74, acquiring 3,333, 100,000, and 50,000 common shares respectively.
• The filing notes that total options and exercise prices are subject to adjustment due to previous reverse stock splits (1:30 on 2/26/2025 and 1:15 on 6/6/2023).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on past transactions related to an acquisition rather than providing new operational or financial performance data.

Positives

• The disposal of shares was part of a court-approved business arrangement, indicating a structured and compliant exit for the former director.
• The exercise of stock options suggests that the reporting person may have benefited from the company's stock performance prior to the acquisition.
• The acquisition of Aptose Biosciences by Hammi Pharmaceuticals Co. Ltd. at C$2.41 per share represents a definitive transaction for shareholders.

Negatives

• The filing details the disposal of securities, which is a reduction in beneficial ownership for the reporting person.
• The exercise of options at prices higher than the implied acquisition price for some options ($2.00 option vs. $1.72 effective disposal price) could represent a loss on those specific option exercises if not offset by other gains.

Risks

• The filing mentions that total options and option exercise prices are subject to adjustment as a result of previous reverse stock splits, which could impact the final value of outstanding options.
• The business arrangement agreement with Hammi Pharmaceuticals Co. Ltd. signifies a change in control and potential strategic shifts for Aptose Biosciences.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from management regarding future company performance. The primary focus is on reporting past transactions related to an acquisition.

Management Comments

• Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
• Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
• Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date.
• TOTAL OPTIONS AND OPTION EXERCISE PRICE SUBJECT TO ADJUSTMENT AS A RESULT OF THE ISSUER'S 1:30 REVERSE STOCK SPLIT ON 2/26/2025 AND 1:15 REVERSE STOCK SPLIT ON 6/6/2023.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant event for Aptose Biosciences, namely its acquisition by Hammi Pharmaceuticals. Such filings are common during M&A activities, detailing the final transactions of key insiders as the company transitions ownership.

Management Changes

Legal Proceedings

• The disposal of shares was part of a business arrangement agreement that was approved by the board, shareholders, and court.

Related Party Transactions

• The disposal of 17,000 common shares by Bernd R. Seizinger was part of a business arrangement agreement with Hammi Pharmaceuticals Co. Ltd., where a subsidiary of Hammi acquired all outstanding shares of Aptose Biosciences.

Stakeholder Impact

• Shareholders: The filing confirms the acquisition of Aptose Biosciences by Hammi Pharmaceuticals at C$2.41 per share, providing a clear exit price for shareholders.
• Former Management/Insiders: Bernd R. Seizinger, a former director, has completed transactions related to the acquisition, as detailed in the filing.
• Employees: The acquisition by Hammi Pharmaceuticals may lead to changes in employment or company structure.

Next Steps

• The acquisition of Aptose Biosciences by Hammi Pharmaceuticals Co. Ltd. is completed, signifying a change in control and ownership structure.

Key Dates

Keywords

Form 4, Aptose Biosciences, Bernd R. Seizinger, Stock Options, Common Shares, Beneficial Ownership, Insider Trading, SEC Filing, Hammi Pharmaceuticals, Business Arrangement